Initial Combining Lamivudine And Adefovir Dipivoxil And Lamivudine/Entecavir Monotherapy In Hepatitis B E Antigen-Positive Chronic Hepatitis B With High Viral Load
jing you,h e liu,h y chen,xian feng,l zhuang,w b yang,hutcha sriplung,alan geater,virasakdi chongsuvivatwong,s j ma,y h che,j h huang,s m yan,r y zhang,s f rao
DOI: https://doi.org/10.1016/j.ijid.2014.03.1085
IF: 12.073
2014-01-01
International Journal of Infectious Diseases
Abstract:Background: Long-term treatment with nucleos(t)ide analogues (NUCs) is highly effective but HBeAg seroconversion and HBsAg loss are very rare and unsatisfied event in CHB patients with high viral load and, the resistance mutation and high relapse rates block benefit from antiviral treatment as well. The aim of the present study is to evaluate the efficacy and safety of a new therapeutic strategy initial combining Lamivudine(LAM) and Adefovir dipivoxil(ADV) in patients with HBeAg-positive chronic hepatitis B(CHB). Methods & Materials: One hundred and Eighty-two treatment-naive CHB patients with HBeAg-positive and HBVDNA≥105copies/ml were included and randomly divided into three treatment groups, LAM monotherapy, entecavir(ETV) monotherapy, and LAM+ADV combination therapy. The patients in LAM+ADV group were treated with combination LAM(100 mg/day) plus ADV(10 mg/day). LAM and ETV group received LAM(100 mg/day) and ETV(0.5 mg/day) alone respectively. Serum levels of ALT, creatinine, HBsAg, HBeAg and HBV viral load, together with genotypic resistence were analyzed at 0,12,24,48,104 weeks, respectively. Results: Of the 182 patients, the majority(82.5%) had serum levels of HBVDNA over 107copies/ml. Baseline characteristics as for HBV viral load, HBsAg and HBeAg titer, median age, serum levels of ALT and creatinine were comparable between three groups. No significant differences in the rates of HBVDNA undetectable(<1000 copies/ml), HBeAg seroconversion, and ALT normalization were found between LAM+ADV and ETV group at 12,24,48 and 104 weeks(p > 0.05). However, these parameters were significant higher in LAM+ADV and ETV group than those of LAM monotherapy group, all with p value less than 0.05,0.01 and 0.001. Compared with LAM monotherapy, ADV+LAM and ETV had an higher response rates at weeks 12,24,48 and 104. HBV viral load dropped sharply during the first four weeks. In 46%,49%;79%,78%;and 95%,92% patients, the level became undetectable from week 24,48 and 104, respectively. HBVDNA breakthrough was detected in 1.67%(ETV) and 36.1%(LAM) of monotherapy and 11.5% of combination therapy patients. The M204 V/I mutation was detected in 1.67%,34.4% and 11.5% of each group, respectively. No elevated serum creatinine were found in three groups through the therapy course. Conclusion: Lower rates of resistance, lower serum HBVDNA levels and higher rates of HBeAg seroconversion were seen in the combination therapy after two years.